Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.-MedSci.cn

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.

Powles, T; Plimack, ER; Stus, V; Waddell, T; Gafanov, R; Pouliot, F; Nosov, D; Melichar, B; Soulieres, D; Borchiellini, D; Vynnychenko, I; McDermott, RS; Azevedo, SJ; Tamada, S; Kryzhanivska, A; Li, C; Burgents, JE; Molife, LR; Rini, BI; Bedke, J

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务